Daewoong Bio launches hyperlipidemia drug mixing rosuvastatin with Omega-3

Daewoong Bio said Wednesday that it launched a hyperlipidemia treatment, CRA-TG Soft Capsule.

CRA-TG combines the hyperlipidemia drug rosuvastatin and unsaturated fatty acid omega-3. Omega-3 is used as a dietary supplement to reduce triglyceride levels in patients with high triglycerides.

Daewoong Bio said that this new product launch is part of expanding its hyperlipidemia treatment lineup. Currently, Daewoong Bio's hyperlipidemia treatment products total nine, including Daewoong Bio Atorvastatin Tablets (atorvastatin), Kratin Tablets (rosuvastatin), Aeze (atorvastatin + ezetimibe), Roeze (rosuvastatin + ezetimibe), and Oma-TG Soft Capsule (omega-3).

According to Daewoong Bio, CRA-TG has been proven to improve lipids, such as total cholesterol (TC), triglycerides (TG), and non-high-density lipoprotein (non-HDL-C), as well as tolerability and stability, compared to rosuvastatin alone.

In addition, the patented Multi-Layer Capsule Coating Technology has been applied. Coating rosuvastatin on the surface of the omega-3 soft capsule prevents each ingredient, omega-3 and rosuvastatin, which have different properties, from affecting each other and secures safety by preventing moisture and air from the outside. By applying soft capsule patented technology, it was developed in a similar size to the existing omega-3 single product Oma-TG.

“According to the Korean Society of Lipid and Atherosclerosis, two out of five adults in Korea suffer from hyperlipidemia, but only about half of hyperlipidemia patients are taking lipid-lowering drugs,” said Koh Jae-ho, product manager at Daewoong Bio. “Given the relatively high triglyceride levels of Koreans compared to other countries, there is a high demand for omega-3-statin combination drugs, and CRA-TG, which combines two (rosuvastatin-omega-3) drugs in one pill, will improve compliance among hyperlipidemia patients.”